Insider · CIK 0001864917
Shalabh K. Gupta
Files at UNCY (Unicycive Therapeutics, Inc.). First filing -, latest -.
In brief
Shalabh K. Gupta files SEC Form 4 as CEO and director at UNCY (Unicycive Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Shalabh K. Gupta has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +762,200 | $0.00 | $0 | 762,200 | Jun 15, 2026 |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +762,200 | $0.00 | $0 | 762,200 | May 21, 2026 |
| Jul 28, 2025 | UNCY Unicycive Therapeutics, Inc. | AGrant or award Stock Optionsderivative | +325,000 | $0.00 | $0 | 968,951 | Jul 30, 2025 |
Questions about Shalabh K. Gupta
Answered from the filings on this page, as of the latest one.
Is Shalabh K. Gupta buying or selling?
Shalabh K. Gupta has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Shalabh K. Gupta's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Shalabh K. Gupta has 0.
Where does Shalabh K. Gupta file Form 4?
Shalabh K. Gupta has filed Form 4 at UNCY (Unicycive Therapeutics, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.